The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Studies Presented at 2010 Genitourinary Cancers Symposium Advance Management, Treatment of Prostate and Bladder Cancers


FOR IMMEDIATE RELEASE: March 3, 2010 

Contact: Aaron Tallent
571-483-1371
aaron.tallent@asco.org

-- Investigational Chemotherapy Drug Prolongs Survival in Advanced Prostate Cancer; Novel Urine Test Could Reduce Need for Biopsies in Men with High PSA Levels; Costly Urine Tests Do Not Improve Tumor Detection in Monitoring for Bladder Cancer Recurrence; Hormone Therapy Plus Radiation Improves Survival, Reduces Recurrence i Intermediate-Risk Early-Stage Prostate Cancer --

SAN FRANCISCO – New studies on the treatment of genitourinary cancers were released today in advance of the third annual Genitourinary Cancers Symposium, being held March 5-7, 2010, at the San Francisco Marriott.

The results of four studies were highlighted in a media presscast (press briefing via live webcast):

  • Investigational chemotherapy drug increases survival for advanced prostate cancer: An international phase III clinical trial reports that a new chemotherapy drug called cabazitaxel increases survival by 30 percent in men, compared with standard therapy, with metastatic prostate cancer that has progressed despite docetaxel-based chemotherapy. There are currently no effective treatments in this setting.
  • Molecular urine test predicts outcomes of prostate biopsy: A sub-analysis from a large prostate cancer prevention trial finds that the PCA3 urine test accurately predicts whether a prostate biopsy will reveal cancer – findings that may help guide prostate biopsy decisions in men suspected to have prostate cancer.
  • Adding hormone therapy to radiation improves survival, reduces recurrence in men with intermediate-risk early-stage prostate cancer: A large phase III study reports that men with early-stage prostate cancer who are at increased risk of recurrence live longer and are less likely to experience a recurrence when they receive short-term hormone therapy before and during moderate-dose radiation therapy compared with men who receive radiation therapy alone.
  • Adding urine biomarker tests to standard cystoscopy is not cost-effective for bladder cancer surveillance: Analysis demonstrates that routinely adding urine tests to out-patient cystoscopy unnecessarily increases the cost of monitoring for bladder cancer recurrence and the risk of a false-positive result, but does not improve tumor detection.

“Having a new chemotherapy drug for advanced prostate cancer is a very exciting development. Increasing survival among patients with advanced disease is a difficult feat, and a major step forward in clinical cancer research,” said Nicholas J. Vogelzang, MD, Chair and Medical Director of the Developmental Therapeutics Committee of US Oncology, who moderated today’s presscast. “Other important studies presented today will help inform the use of new biomarker tests to diagnose and monitor genitourinary cancers, and recognize their limitations.”

Genitourinary cancers include those of the prostate, kidney, bladder and testis, as well as less common cancers such as those of the penis, ureters and other urinary organs. Each year more than 332,000 people in the United States are diagnosed with genitourinary cancers and more than 56,000 die of these diseases. The most common genitourinary cancer is prostate cancer, which is diagnosed in more than 192,000 men and claims more than 27,000 lives each year.


The Genitourinary Cancers Symposium is co-sponsored by the American Society for Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

For the full release, click here.

More information for media: 2010 Genitourinary Cancers Symposium Press Kit

Relevant links on ASCO's patient information site, Cancer.Net:

• 2010 GU Cancers Symposium Cancer Advances
• 2010 GU Cancers Symposium Podcast
• Cancer.Net Guide to Prostate Cancer
• ASCO Answers – Prostate Cancer
• ASCO Answers – Prostate Cancer (Spanish)
• Cancer.Net Guide to Bladder Cancer
• ASCO Answers – Bladder Cancer
• Types of Treatment
• Understanding Chemotherapy
• What to Know about Hormone Therapy for Advanced Prostate Cancer
• Talking With the Doctor About PSA Screening
• Clinical Trials
• Endoscopic Techniques





 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005–2012 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.
Feedback Form